Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Enveric Biosciences, Inc. (ENVB)

Enveric Biosciences files prospectus for $2.425 million more in at-the-market share sales

Neutral Impact 2 of 5 financing Written later

Enveric Biosciences filed a prospectus supplement on June 9, 2026, to offer an additional $2,425,000 of common stock through its existing at-the-market sales agreement with H.C. Wainwright & Co. The company has previously sold $4,483,711.04 of shares under that agreement, which dates to April 9, 2025. The filing adds to potential dilution for existing shareholders, but it does not disclose a financial result or a change in business operations.

Key points

  • Additional offering amount: $2,425,000 of common stock under the ATM Agreement dated April 9, 2025
  • Sales to date under the ATM Agreement before this filing: $4,483,711.04
  • Sales agent: H.C. Wainwright & Co., LLC; legal opinion filed as Exhibit 5.1 from Greenberg Traurig, LLP

The filing

CompanyEnveric Biosciences, Inc. (ENVB)
Form8-K, current report
Filed with the SECJun 9, 2026, 5:16 PM ET
Accession number0001493152-26-027976

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 09, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.